Zobrazeno 1 - 10
of 19
pro vyhledávání: ''
Autor:
Luigi Formisano, Erika Martinelli, Matilde Lambiase, Francesca Fenizia, Roberto Bianco, Floriana Morgillo, Fortunato Ciardiello, Giulia Martini, Donata Vitagliano, Teresa Troiani, Claudia Cardone, Nicola Normanno, Davide Ciardiello, Stefania Napolitano
Publikováno v:
Clinical Cancer Research. 21:4153-4164
Purpose: The use of cetuximab in the treatment of metastatic colorectal cancer is limited by development of resistance. Experimental Design: We have investigated in three models of highly epidermal growth factor receptor (EGFR)–dependent colorectal
Autor:
Maria E. Arcila, Efsevia Vakiani, Jaclyn F. Hechtman, Jason T. Huse, Jinru Shia, Laetitia Borsu, Rona Yaeger, Justyna Sadowska, Marc Ladanyi
Publikováno v:
Molecular Cancer Research. 13:1003-1008
The PI3K/AKT/mTOR pathway is activated through multiple mechanisms in colorectal carcinoma. Here, the clinicopathologic and molecular features of AKT1 E17K–mutated colorectal carcinoma in comparison with PIK3CA-mutated colorectal carcinoma are desc
Autor:
Noelia Ferruz, Israel Cañadas, Alba Dalmases, Joaquim Bellmunt, Marta Salido, Federica Di Nicolantonio, Giorgio Corti, Alberto Bardelli, Mar Iglesias, Juan Sánchez, Giovanni Crisafulli, Elena Gavilán, Sandra Misale, Alejandro Martínez, Joan Albanell, Clara Montagut, Iria Gonzalez, Gianni De Fabritiis, Beatriz Bellosillo, Mariangela Russo, Giulia Siravegna, Sabrina Arena, Ana Rovira, Sebastijan Hobor, Luca Lazzari
Publikováno v:
Clinical Cancer Research. 21:2157-2166
Purpose: Patients with colorectal cancer who respond to the anti-EGFR antibody cetuximab often develop resistance within several months of initiating therapy. To design new lines of treatment, the molecular landscape of resistant tumors must be ascer
Autor:
Chen Jiang, Alan P. Venook, Alexander B. Sibley, Ivo D. Shterev, Kouros Owzar, Herbert Hurwitz, Stephanie M. Cushman, Andrew B. Nixon, Donna Niedzwiecki, Ace J. Hatch
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 21, iss 5
Purpose: Formalin-fixed, paraffin-embedded tumor samples from CALGB 80203 were analyzed for expression of EGFR axis–related genes to identify prognostic or predictive biomarkers for cetuximab treatment. Patients and Methods: Patients (238 total) wi
Autor:
Beth O. Van Emburgh, Sebastijan Hobor, Federica Di Nicolantonio, Alberto Bardelli, Sandra Misale, Emily Crowley
Publikováno v:
Clinical Cancer Research. 20:6429-6438
Purpose: Targeted inhibition of EGFR with the mAbs cetuximab or panitumumab is a valuable treatment for RAS wild-type colorectal cancers. The efficacy of EGFR blockade is limited by the emergence of acquired resistance often attributed to secondary K
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 24:1416-1418
In metastatic colorectal cancer, KRAS and NRAS genotyping is mandatory before prescription of panitumumab or cetuximab. In order to perform such molecular tests, the French National Cancer Institute has set up a nationwide network of molecular center
Autor:
Somy Yoon, Sung Pil Hong, Ik Joo Chung, So Yeon Park, Jun Eul Hwang, Jeong A Bae, Kyung Keun Kim, Jae Hyuk Lee, Yoon Jin Cha, Hoguen Kim, Hangun Kim, Young Woo Seo
Publikováno v:
Clinical Cancer Research. 20:4115-4128
Purpose: EGF-stimulated signaling via EGF receptor (EGFR) is important in colorectal tumorigenesis and drug targeting. However, anti-EGFR therapy is not effective in a subset of patients with colorectal cancer, suggesting that unidentified EGF-stimul
Autor:
Stephen H. Friend, Brian Dougherty, Robert McEwen, Gilles Manceau, Pierre Laurent-Puig, Justin Guinney, Jonathan R. Dry, Erich Huang, Jean-Charles Soria, Michel Ducreux, Kai-Ming Chang, Jonathan M. J. Derry, KJ Kao, Charles Ferté, Kevin Hudson, Claus Bendtsen
Publikováno v:
Clinical Cancer Research. 20:265-272
Purpose: KRAS wild-type status is an imperfect predictor of sensitivity to anti-EGF receptor (EGFR) monoclonal antibodies in colorectal cancer, motivating efforts to identify novel molecular aberrations driving RAS. This study aimed to build a quanti
Autor:
Federica Di Nicolantonio, Francesco Galimi, Paolo Massucco, Andrea Bertotti, Alberto Bardelli, Eugenia R. Zanella, Michela Buscarino, Giorgia Migliardi, Livio Trusolino, Lorenzo Capussotti, Davide Torti, Dario Ribero, Silvia Marsoni, Francesco Sassi, Mauro Risio, Alberto Pisacane, Paolo M. Comoglio, Andrea Muratore
Publikováno v:
Clinical Cancer Research
Clinical Cancer Research; Vol 18
Clinical Cancer Research; Vol 18
Purpose: Gene mutations along the Ras pathway (KRAS, NRAS, BRAF, PIK3CA) occur in approximately 50% of colorectal cancers (CRC) and correlate with poor response to anti–EGF receptor (EGFR) therapies. We assessed the effects of mitogen-activated pro
Autor:
Nadia Russolillo, Salvatore Siena, Enzo Medico, Michela Buscarino, Federica Di Nicolantonio, Davide Torti, Paolo Massucco, Alberto Bardelli, Alberto Pisacane, Luca Molinaro, Francesco Galimi, Andrea Bertotti, Mauro Risio, Davide Corà, Emanuele Valtorta, Giorgia Migliardi, Francesco Sassi, Claudio Isella, Lorenzo Capussotti, Paolo M. Comoglio, Andrea Muratore, Anna Sapino, Consalvo Petti, Livio Trusolino, Silvia Marsoni, Andrea Sartore-Bianchi, Marcello Gambacorta, Dario Ribero
Publikováno v:
Cancer Discovery; Vol 1
Only a fraction of patients with metastatic colorectal cancer receive clinical benefit from therapy with anti-epidermal growth factor receptor (EGFR) antibodies, which calls for the identification of novel biomarkers for better personalized medicine.